Press Releases

Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated

On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy on February 28 , at 4:30 p.m. ET Plans to present interim data from ongoing first-in-human study of NTLA-2002 for hereditary

State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies New facility in Waltham, Massachusetts expected to be operational in 2024 CAMBRIDGE, Mass. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

Fourth quarter and full-year 2021 financial results – February 24 , at 8:00 a.m. ET Updated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis – February 28 , at 4:30 p.m. ET CAMBRIDGE, Mass. , Feb.

Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic

Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategies Acquisition further expands Intellia’s industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing

Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from Phase 1 study in Q1 2022 Achieve preliminary proof-of-concept for NTLA-2002 in patients with hereditary angioedema (HAE) based on ongoing

CAMBRIDGE, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the

• Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases
   
• Kyverna to lead and fund preclinical and clinical development; Intellia to receive option

CAMBRIDGE, Mass. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , today announced the appointment of Derek Hicks to a newly created